eli lilly new glp 1 is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Eli Lilly Nails Oral GLP-1

Description

[DOI] [PubMed] [Google Scholar] 109.Bartholdy K.V., Johansen N.D., Skaarup K.G., Modin D., Landler N., Langhoff A.F., Ottosen C.:I., Espersen C., Dons M., Borchsenius J.I.M., et al

think people are celebrating it

doi: 10.1016/j.cmet.2019.07.013 58 BergmannNCLundAGasbjergLSMeessenECEAndersenMMBergmannSet al

Cuomo, A

Red flag symptoms requiring urgent assessment: Severe, persistent vomiting Inability to tolerate oral intake for more than 24 hours, suggesting possible gastroparesis or other complications Signs of dehydration Decreased urine output, dizziness, dry mucous membranes, or tachycardia Severe abdominal pain Particularly if acute, localized, or associated with fever, which may indicate pancreatitis or other acute abdominal pathology Right upper quadrant pain, fever, or jaundice Suggesting possible gallbladder disease Severe abdominal distension with inability to pass stool or gas Potential bowel obstruction or ileus Hematemesis or melena Suggesting gastrointestinal bleeding Progressive dysphagia Difficulty swallowing that worsens over time Situations requiring routine consultation: Patients should contact their healthcare provider for non-urgent evaluation when experiencing persistent nausea or vomiting lasting beyond 2-3 weeks at a stable dose, as this may indicate inadequate adaptation or the need for dose adjustment